{"gene":"GNAO1","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":1996,"finding":"Gαo and Gαi2 are expressed in distinct subsets of vomeronasal sensory neurons and are enriched in VNO microvilli, indicating roles in pheromone sensory transduction via separate G-protein-coupled cascades alongside adenylyl cyclase type II.","method":"In situ hybridization, immunohistochemistry, cDNA cloning","journal":"The Journal of Neuroscience","confidence":"Medium","confidence_rationale":"Tier 3 — localization with functional inference but no direct reconstitution; replicated across methods in same study","pmids":["8558259"],"is_preprint":false},{"year":2000,"finding":"H2O2 directly activates purified heterotrimeric Go (but not Gs) in vitro by modifying Gαo, leading to subunit dissociation and subsequent Gβγ-dependent ERK activation, identifying Gαo as a direct target of reactive oxygen species.","method":"In vitro [35S]GTPγS binding assay with purified proteins, cardiomyocyte cell experiments, Gβγ inhibition","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified proteins plus mutagenesis/inhibitor controls; strong evidence","pmids":["11100733"],"is_preprint":false},{"year":2000,"finding":"Gαo is required for the light response of ON bipolar neurons: mice lacking Gαo show complete absence of the b-wave of the ERG while rod/cone photocurrents (a-wave) and retinal architecture are normal, establishing Gαo as the essential G protein in the mGluR6 cascade.","method":"Knockout mouse (Gαo−/−), electroretinography","journal":"The Journal of Neuroscience","confidence":"High","confidence_rationale":"Tier 2 — clean genetic knockout with specific physiological phenotype; replicated across rod- and cone-driven components","pmids":["11124982"],"is_preprint":false},{"year":1994,"finding":"Intraneuronal antibody microinjection established that Gαo (not Gαq/11) mediates α-adrenoceptor inhibition of N/L-type Ca2+ current in sympathetic neurons, while Gαq/11 mediates muscarinic inhibition of M-current.","method":"Intracellular antibody microinjection in SCG neurons, patch-clamp electrophysiology","journal":"The Journal of Physiology","confidence":"High","confidence_rationale":"Tier 1-2 — selective antibody microinjection with electrophysiological readout; highly cited foundational study","pmids":["7932231"],"is_preprint":false},{"year":1997,"finding":"Gαo is required for muscarinic inhibition of L-type Ca2+ channels in ventricular myocytes; Gαo−/− mice show no muscarinic inhibition of L-type Ca2+ current while isoproterenol responses and muscarinic regulation of atrial K+ channels remain normal.","method":"Homologous recombination knockout mouse, whole-cell patch clamp in ventricular myocytes","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with specific electrophysiological readout; two independent phenotypes tested","pmids":["9050846"],"is_preprint":false},{"year":2005,"finding":"Gαo/i directly interacts with Rap1GAPII and promotes its ubiquitination and proteasomal degradation, thereby activating Rap1 and inducing neurite outgrowth downstream of the CB1 cannabinoid receptor in Neuro-2A cells.","method":"Co-immunoprecipitation, proteasomal inhibitor (lactacystin), siRNA, dominant-negative constructs, pertussis toxin","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (protein interaction, genetic, pharmacological) in same study","pmids":["15657046"],"is_preprint":false},{"year":2005,"finding":"Gαo/i-coupled CB1 receptor sequentially activates Rap1→Ral→Src→Stat3 and also Rac1→JNK→Stat3 pathways for neurite outgrowth; Src activation requires both Rap1 and Ral downstream of Gαo.","method":"Dominant-negative and constitutively active mutant overexpression, pharmacological inhibitors, phosphorylation assays in Neuro-2A cells","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — epistasis established by multiple dominant-negative constructs and pharmacological inhibitors; strong within-study evidence","pmids":["16046413"],"is_preprint":false},{"year":2008,"finding":"Gαo mediates WNT3a-JNK (planar cell polarity) signaling in mammalian F9 cells through Dishevelled-1 and Dishevelled-3 (but not Dvl-2), RhoA/Rac1/Cdc42, and MEKK1/MEKK4, independently of Gαq; Gαo is not required for canonical WNT-β-catenin signaling alone.","method":"Epistasis with dominant-negative/shRNA, Dapper1 antagonist, chemical inhibitors, RhoA/Rac1/Cdc42 activation assays in mouse F9 teratocarcinoma cells","journal":"Journal of Cell Science","confidence":"High","confidence_rationale":"Tier 2 — systematic epistasis with multiple orthogonal genetic and pharmacological tools","pmids":["18187455"],"is_preprint":false},{"year":2011,"finding":"Conditional deletion of Gαo in vomeronasal sensory neurons abolishes electrophysiological and Ca2+ responses to MHC class I antigens, major urinary proteins, and N-formylated mitochondrial peptides (V2R neuron ligands), and eliminates male-male and maternal territorial aggression.","method":"Cre-loxP conditional knockout, extracellular field recordings, calcium imaging, behavioral tests","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — clean conditional KO with multiple electrophysiological and behavioral readouts; multiple ligands tested","pmids":["21768373"],"is_preprint":false},{"year":2011,"finding":"The oncogenic Gαo R243H mutation accelerates guanine nucleotide exchange (constitutive activation) without impairing GTPase activity or GAP sensitivity; the mechanism involves loss of a conserved R243-E43 electrostatic interaction in the P-loop. Constitutively active Gαo R243H enhances Src-STAT3 signaling to promote cellular transformation.","method":"Limited proteolysis, nucleotide-binding assays, single-turnover and steady-state GTPase assays, mutagenesis, NIH-3T3 transformation assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — multiple in vitro enzymatic assays with mutagenesis and structural analysis in same study","pmids":["21317923"],"is_preprint":false},{"year":2013,"finding":"De novo GNAO1 mutations cause epileptic encephalopathy; mutations predicted to destabilize the Gα fold impair plasma membrane localization, while the Gly203Arg switch-II mutation impairs GTP binding/downstream effector activation. All four mutants show reduced Gαo-mediated inhibition of calcium currents by norepinephrine.","method":"Whole-exome sequencing, transient expression with immunofluorescence localization, electrophysiological calcium current recording, 3D structural modeling","journal":"American Journal of Human Genetics","confidence":"High","confidence_rationale":"Tier 2 — functional assays (Ca2+ current electrophysiology, localization) plus structural analysis across multiple mutants","pmids":["23993195"],"is_preprint":false},{"year":2001,"finding":"The N-terminus of Gαo directly binds the C-terminus of the α1A (P/Q-type, Cav2.1) Ca2+ channel subunit in vitro, and this interaction mediates voltage-resistant (but not voltage-dependent) inhibition of α1A Ca2+ currents; Gβγ mediates the voltage-dependent component.","method":"In vitro binding assay with peptides/antisera, patch-clamp electrophysiology with peptide/antibody dialysis","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding reconstitution with blocking peptides/antibodies and direct electrophysiological functional validation","pmids":["11395521"],"is_preprint":false},{"year":1995,"finding":"Voltage-dependent Ca2+ channel β-subunits act as GTPase-activating proteins for Gαo in rat frontal cortex membranes; an anti-β-subunit antiserum and a peptide mimicking the β-subunit binding domain both abolish dihydropyridine agonist-stimulated GTP hydrolysis by Go.","method":"GTPase assay in cortical membranes, antibody and peptide inhibition, [3H]dihydropyridine binding","journal":"FEBS Letters","confidence":"Medium","confidence_rationale":"Tier 2 — membrane-based enzymatic assay with antibody and peptide blocking; single study","pmids":["7544301"],"is_preprint":false},{"year":1995,"finding":"The C-terminal region and amino-terminal contacts (β-strands 1 and 3) of Gαo determine its characteristic nucleotide binding and conformation properties; C-terminal truncation of 14 residues decreases GDP affinity and reveals a GTP-activated conformation in Gαo but not Gαi2, a difference mapped to hydrophobic residues 11-13 from the C-terminus.","method":"In vitro translation, native tryptic proteolysis, chimeric Gαo/Gαi2 protein analysis, nucleotide binding assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis and structural correlation","pmids":["7727415"],"is_preprint":false},{"year":2000,"finding":"Mu-opioid receptor co-immunoprecipitates with Gαo, Gαi1, and Gαi3 (but not Gαs or Gαq/11) from solubilized rat brain in a GTPγS-sensitive manner, demonstrating direct receptor-G protein coupling.","method":"Immunoprecipitation from solubilized rat brain, [3H]DAMGO binding, GTPγS competition","journal":"Journal of Neurochemistry","confidence":"Medium","confidence_rationale":"Tier 3 — co-immunoprecipitation from native tissue; GTPγS sensitivity confirms functional complex","pmids":["10693938"],"is_preprint":false},{"year":1998,"finding":"Human substance P receptor directly activates Gαq/11, Gαs, and Gαo in CHO cell membranes, as shown by photoaffinity labeling of Gα subunits with [32P]AA-GTP upon receptor stimulation followed by immunoprecipitation.","method":"Photoaffinity labeling ([32P]azidoanilido-GTP), immunoprecipitation with subunit-specific antibodies","journal":"FEBS Letters","confidence":"Medium","confidence_rationale":"Tier 2 — direct covalent labeling of activated Gα subunits in membrane preparations; single study","pmids":["9654151"],"is_preprint":false},{"year":2003,"finding":"G protein subunit Gγ13 is coexpressed with Gαo, Gβ3, and Gβ4 specifically in retinal ON bipolar cell dendrites (not OFF), identifying the specific heterotrimer (Gαo/Gβ3 or Gβ4/Gγ13) mediating ON bipolar phototransduction.","method":"Immunohistochemistry, GFP-transgenic mouse single-cell RT-PCR, patch-clamp identification","journal":"Journal of Comparative Neurology","confidence":"Medium","confidence_rationale":"Tier 2 — colocalization at protein level in identified cell types confirmed by single-cell PCR; multiple methods in same study","pmids":["12454992"],"is_preprint":false},{"year":2014,"finding":"A gain-of-function knock-in mutation (G184S) preventing RGS-mediated GTPase acceleration in Gαo causes epileptiform discharges, seizures, and strain-dependent lethality in mice, demonstrating that constitutive Gαo activity (failure of turnoff) drives epileptic encephalopathy.","method":"Genomic knock-in mouse, EEG recording, pentylenetetrazol kindling, genetic modifier mapping","journal":"Mammalian Genome","confidence":"High","confidence_rationale":"Tier 2 — defined knock-in with mechanistic interpretation (RGS resistance) and specific EEG phenotype","pmids":["24700286"],"is_preprint":false},{"year":2017,"finding":"GNAO1 clinical mutations segregate into loss-of-function (reduced cAMP inhibition, associated with epileptic encephalopathy) and gain-of-function (lower EC50 for α2A-AR-mediated cAMP inhibition, including G42R, G203R, E246K; associated with movement disorders), establishing a functional correlation with clinical phenotype.","method":"Site-directed mutagenesis, HEK-293T expression, Western blot, cAMP inhibition assay with co-expressed α2A-adrenergic receptor","journal":"Neurology","confidence":"High","confidence_rationale":"Tier 2 — 15 clinical variants systematically tested with functional cAMP assay; strong in vitro mechanistic classification","pmids":["28747448"],"is_preprint":false},{"year":2020,"finding":"Co-immunoprecipitation and mass spectrometry identified SPTAN1 (α-II spectrin) as an interacting partner of Gαo; GNAO1 silencing attenuates neurite outgrowth, reduces SPTAN1 and Ankyrin-G expression in brain organoids, and impairs synchronized neuronal firing.","method":"Co-immunoprecipitation, mass spectrometry, siRNA knockdown, iPSC-derived brain organoids, calcium imaging","journal":"FASEB Journal","confidence":"Medium","confidence_rationale":"Tier 2-3 — MS-based interaction identification with functional follow-up in multiple systems; single lab","pmids":["33107105"],"is_preprint":false},{"year":2022,"finding":"The three most common encephalopathy mutations (Gly203, Arg209, Glu246) accelerate GTP uptake and inactivate GTP hydrolysis by displacing Gln205 critical for catalysis, resulting in constitutive GTP binding but failure to adopt the active conformation. Zn2+ restores GTPase activity and cellular interactions of these mutants without affecting wild-type Gαo.","method":"In vitro GTPase assay, nucleotide binding assay, protein-protein interaction assay, high-throughput drug screening, Drosophila model","journal":"Science Advances","confidence":"High","confidence_rationale":"Tier 1 — multiple in vitro enzymatic assays, structural analysis, and in vivo rescue in same study","pmids":["36206333"],"is_preprint":false},{"year":2022,"finding":"All tested GNAO1 pathological mutations (G42R, G203R, R209C) result in loss of function in C. elegans goa-1 models and also exhibit dominant-negative effects in heterozygous animals; G42R dominant-negative effects were confirmed in mice impairing motor behaviors.","method":"CRISPR/Cas9 knock-in in C. elegans and mouse, behavioral assays, transgenic overexpression","journal":"Human Molecular Genetics","confidence":"High","confidence_rationale":"Tier 2 — conserved findings across two animal models with CRISPR alleles and transgenic confirmation","pmids":["34508586"],"is_preprint":false},{"year":2021,"finding":"Gln52 mutations in Gαo (Q52P, Q52R) abolish GTP binding and hydrolysis; the mutant proteins are defective in interaction with GDP-loaded and GTP-loaded partner proteins, and show strongly reduced plasma membrane localization with accumulation at non-membrane sites.","method":"In vitro GTP binding and hydrolysis assays, co-immunoprecipitation, immunofluorescence localization in mammalian cells","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1-2 — enzymatic assays plus protein interaction and localization studies with mutagenesis","pmids":["34685729"],"is_preprint":false},{"year":2024,"finding":"GNAO1 encephalopathy mutants gain aberrant neomorphic interactions with both Ric8A and Ric8B chaperones (Ric8B normally handles only Gαs/olf), relocalizing them from cytoplasm to Golgi. This neomorphic Ric8 sequestration imbalances neuronal G protein signaling networks and mediates disease dominance; the strength of Gαo-Ric8B interaction correlates with disease severity.","method":"Co-immunoprecipitation, immunofluorescence colocalization, systematic characterization of >80 pathological Gαo variants for GTP handling and partner binding","journal":"The Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 — systematic multi-variant characterization with orthogonal protein interaction and localization assays; novel mechanism with strong evidence","pmids":["38874642"],"is_preprint":false},{"year":2021,"finding":"GNAO1-encoded Gαo is transcriptionally regulated by NRSF in the heart; increased cardiac Gαo elevates L-type Ca2+ channel surface activity, activates CaMKII signaling, and impairs Ca2+ handling in ventricular myocytes, causing cardiac dysfunction.","method":"Cardiac-specific NRSF knockout mice, dominant-negative NRSF mice, cardiac-specific Gnao1 overexpression transgenic mice, Gnao1 genetic knockdown, L-type Ca2+ channel current recording","journal":"Circulation Research","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic mouse models with defined electrophysiological and functional readouts","pmids":["34875852"],"is_preprint":false},{"year":2008,"finding":"Cardiac-specific expression of constitutively active Gαo1* enhances L-type Ca2+ channel current density, calcium transients, and contractile function, associated with increased phosphorylation of ryanodine receptor and phospholamban via reduced protein phosphatase 1 activity (not PKA).","method":"Transgenic mice with cardiac-specific constitutively active Gαo*, whole-cell patch clamp, Ca2+ transient measurement, phosphorylation assays, PP1 activity assay","journal":"American Journal of Physiology – Heart and Circulatory Physiology","confidence":"High","confidence_rationale":"Tier 2 — transgenic gain-of-function model with multiple orthogonal mechanistic readouts","pmids":["18192223"],"is_preprint":false},{"year":2024,"finding":"Leu→Pro substitutions at positions 13 and 23 (N-terminal α-helix of Gαo) uniquely destabilize the N-terminal α-helix, blocking heterotrimeric G-protein formation and GPCR-mediated activation, without impairing GTPase activity or overall folding; clinically associated with parkinsonism phenotype.","method":"Structural and biochemical characterization of mutant Gαo proteins, heterotrimeric complex formation assay, GPCR coupling assay","journal":"Movement Disorders","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro biochemical and structural characterization with clear mechanistic distinction from other mutants","pmids":["38358016"],"is_preprint":false},{"year":2024,"finding":"Gαo acts as a molecular switch regulating Rho GTPase signaling in developing neurons; GNAO1 knockdown or the G203R mutation disrupts Rho GTPase-dependent actin cytoskeleton remodeling, growth cone formation, and self-organizing neural rosette assembly; Rho kinase inhibitor Y27632 rescues these morphological phenotypes.","method":"siRNA knockdown in Neuro2a, iPSC-derived neurons and organoids from GNAO1 G203R patient, phospho-MLC2 immunostaining, ROCK inhibitor rescue","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — patient iPSC model plus pharmacological rescue; single lab","pmids":["39048611"],"is_preprint":false},{"year":2002,"finding":"In C. elegans, the N-terminal region of the RGS protein EGL-10 directs selective inhibition of GOA-1 (Gαo) by forming a complex with the GGL/RGS domain and its associated Gβ subunit GPB-2, affecting membrane localization and G protein target selectivity of the RGS domain.","method":"C. elegans transgenic epistasis, chimeric RGS protein analysis, co-immunoprecipitation, subcellular fractionation","journal":"The Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis and co-IP in C. elegans ortholog system; functional relevance to mammalian Gαo regulation","pmids":["12354761"],"is_preprint":false},{"year":2024,"finding":"Gnao1 expressed in Schwann cells (not neurons) negatively regulates myelination: SC-specific Gnao1 deletion elevates cAMP and activates PI3K/AKT signaling to promote SC differentiation and accelerate re-myelination after nerve injury, while Gnao1 overexpression delays re-myelination.","method":"SC-specific Gnao1 conditional knockout and overexpression mice, nerve injury re-myelination assay, cAMP measurement, PI3K/AKT pathway analysis, RNA sequencing","journal":"Acta Neuropathologica Communications","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain- and loss-of-function mouse models with defined cellular and molecular readouts","pmids":["38331815"],"is_preprint":false},{"year":1995,"finding":"αo1 protein levels increase during NGF-induced neurite outgrowth in PC12 cells and correlate with neurite length; the αo1/αo2 ratio increases selectively during differentiation, suggesting Gαo isoform-specific involvement in neuritic extension.","method":"Western blot with isoform-specific antibodies, morphometric measurement of neurite length during NGF treatment","journal":"Developmental Brain Research","confidence":"Low","confidence_rationale":"Tier 3 — correlational protein expression analysis; no direct functional manipulation","pmids":["7493405"],"is_preprint":false},{"year":2009,"finding":"Gnao1 in the locus coeruleus contributes to physical opioid dependence: Gnao1 expression is upregulated in morphine-dependent C57BL/6 but not A/J mice, and antisense knockdown of Gnao1 reduces naloxone-precipitated withdrawal jumping in dependent B6 mice.","method":"Quantitative PCR, antisense oligodeoxynucleotide knockdown, naloxone-precipitated withdrawal behavioral assay, QTL mapping","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2-3 — antisense knockdown with specific behavioral readout; single study but genetic evidence converges","pmids":["19460419"],"is_preprint":false},{"year":2023,"finding":"An intronic GNAO1 c.724-8G>A mutation creates a novel splice acceptor site inserting Pro-Gln in the switch III region; this misconfigures switch III-switch II interactions, increases GTP uptake, and causes defective GTP hydrolysis and aberrant effector protein interactions, while intracellular localization, Gβγ interactions, and GPCR coupling remain unchanged.","method":"NGS diagnostics, RNA splicing analysis, in vitro GTP uptake and hydrolysis assays, protein-protein interaction assays, high-throughput drug screening","journal":"Med","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic characterization with structural interpretation and drug screening validation","pmids":["37001522"],"is_preprint":false},{"year":2024,"finding":"The P170R Gαo mutant displays 100-fold accelerated GTP uptake without loss of GTP hydrolysis (biochemically distinct from all other encephalopathy mutants); Zn2+ uniquely forces the mutant to release bound GTP rather than restoring hydrolysis.","method":"In vitro GTP uptake and hydrolysis assays, Zn2+ treatment, protein interaction assays","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic characterization with mutagenesis; biochemically distinct mechanism demonstrated","pmids":["37887313"],"is_preprint":false},{"year":1989,"finding":"Two Gαo subforms (Gαo-I and Gαo-II) were purified from bovine brain and shown to have distinct peptide maps and migration, with Gαo-II being the only form in NG 108-15 cell membranes; Gαo is highly enriched in nervous tissue and adrenal medulla.","method":"Protein purification, immunochemical characterization, in situ peptide mapping, tissue distribution by immunoblot","journal":"European Journal of Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical protein purification and characterization; foundational structural/distribution finding","pmids":["2506013"],"is_preprint":false},{"year":2022,"finding":"GNAO1 G203R iPSC-derived cortical neurons show aberrant cell fate commitment, reduced early neural gene expression, increased astrocyte markers, premature and defective neuronal differentiation, lower basal intracellular Ca2+ concentration, reduced spontaneous activity frequency, and smaller responses to neurotransmitters.","method":"Patient-derived hiPSC differentiation, CRISPR-corrected isogenic controls, RNA-seq, Ca2+ imaging, electrophysiology","journal":"Heliyon","confidence":"High","confidence_rationale":"Tier 2 — isogenic CRISPR-corrected control with multiple orthogonal functional readouts; findings replicated in second unrelated patient with same variant","pmids":["38434323"],"is_preprint":false},{"year":2001,"finding":"The C-terminal residue at position -3 (Gly) of Gαo is essential for productive interaction with the α2A-adrenoceptor; substitution with Glu (from Gαs) converts agonist clonidine from full agonist to antagonist for GTPγS binding, demonstrating that this single C-terminal residue constrains receptor-G protein coupling specificity.","method":"C-terminal mutagenesis of Gαo, [35S]GTPγS binding assay with co-expressed α2A-adrenoceptor in Sf9 cells","journal":"Molecular Pharmacology","confidence":"Medium","confidence_rationale":"Tier 1-2 — site-directed mutagenesis with functional binding assay; single study","pmids":["11562427"],"is_preprint":false}],"current_model":"GNAO1 encodes Gαo, the most abundant G protein α-subunit in the mammalian brain, which couples GPCRs to multiple effectors: it inhibits N- and L-type voltage-gated Ca2+ channels (via direct N-terminus/α1A interaction and by Gβγ release), mediates mGluR6 signaling in retinal ON bipolar cells, drives pheromone transduction via V2R receptors in vomeronasal neurons, activates Rap1 (through Rap1GAPII proteasomal degradation) and sequential Ral→Src→Stat3 cascades for neurite outgrowth, mediates WNT-JNK planar cell polarity signaling through Dishevelled-1/3 and RhoA/Rac1/Cdc42, and is directly activated by reactive oxygen species; pathogenic GNAO1 mutations disrupt GTP cycling (accelerating uptake and/or blocking hydrolysis), impair Gβγ and RGS interactions, reduce plasma membrane localization, and gain neomorphic interactions with Ric8A/B chaperones, with loss-of-function alleles causing epileptic encephalopathy and gain-of-function alleles primarily causing hyperkinetic movement disorders."},"narrative":{"teleology":[{"year":1989,"claim":"Identification of two biochemically distinct Gαo isoforms enriched in nervous tissue established Gαo as the predominant brain G protein α-subunit and raised the question of which signaling pathways it serves.","evidence":"Protein purification, peptide mapping, and immunoblot tissue survey from bovine brain","pmids":["2506013"],"confidence":"Medium","gaps":["No functional assay for either isoform","No receptor coupling demonstrated"]},{"year":1994,"claim":"Antibody microinjection demonstrated that Gαo (not Gαq/11) mediates α-adrenoceptor inhibition of N/L-type Ca²⁺ channels in sympathetic neurons, establishing the first direct effector link for Gαo.","evidence":"Intracellular anti-Gαo antibody injection with patch-clamp recording in rat SCG neurons","pmids":["7932231"],"confidence":"High","gaps":["Mechanism of channel inhibition (direct vs. Gβγ-mediated) not resolved","Receptor-Gαo coupling specificity determinants unknown"]},{"year":1995,"claim":"Structural studies showed that the C-terminal region and N-terminal β-strands of Gαo determine its unique nucleotide-binding and conformational properties, distinguishing it from Gαi2.","evidence":"In vitro chimeric Gαo/Gαi2 analysis, native proteolysis, and nucleotide binding assays","pmids":["7727415"],"confidence":"High","gaps":["No crystal structure available at this point","Functional consequences of C-terminal truncation in vivo unknown"]},{"year":1996,"claim":"Gαo expression in a distinct subset of vomeronasal sensory neurons suggested a role in pheromone transduction via a dedicated GPCR cascade, though functional proof required later conditional knockout.","evidence":"In situ hybridization and immunohistochemistry in mouse VNO","pmids":["8558259"],"confidence":"Medium","gaps":["No functional ablation of Gαo in VNO neurons","Specific pheromone ligands transduced by Gαo-expressing neurons not identified"]},{"year":1997,"claim":"Gαo knockout mice revealed that Gαo is required for muscarinic inhibition of L-type Ca²⁺ channels in ventricular myocytes, extending Gαo effector biology beyond neurons to the heart.","evidence":"Gαo−/− knockout mouse with whole-cell patch clamp in ventricular myocytes","pmids":["9050846"],"confidence":"High","gaps":["Mechanism of L-type channel regulation (direct vs. indirect) not established","Cardiac phenotype at organ level not fully characterized"]},{"year":2000,"claim":"Three contemporaneous studies resolved key coupling questions: Gαo is the essential G protein for the mGluR6 ON-bipolar cascade (ERG b-wave abolished in knockout), is directly activated by reactive oxygen species (H₂O₂ modifies Gαo causing subunit dissociation and Gβγ-dependent ERK activation), and couples to mu-opioid receptors in brain.","evidence":"Gαo−/− mouse ERG; in vitro GTPγS binding with purified Go plus H₂O₂; co-IP from solubilized rat brain","pmids":["11124982","11100733","10693938"],"confidence":"High","gaps":["Identity of the ROS-modified residue(s) on Gαo unknown","Downstream effectors of Gαo in ON bipolar cells not identified","Mu-opioid receptor coupling shown only by co-IP, not by reconstitution"]},{"year":2001,"claim":"The Gαo N-terminus was shown to directly bind the α1A (Cav2.1) Ca²⁺ channel subunit C-terminus, mediating voltage-resistant inhibition, while Gβγ mediates the voltage-dependent component — resolving a longstanding dual-mechanism question.","evidence":"In vitro peptide binding assay and intracellular peptide/antibody dialysis during patch-clamp recording","pmids":["11395521"],"confidence":"High","gaps":["Structural basis of the Gαo–α1A interaction not resolved","Relative contribution of each mechanism in intact synapses unknown"]},{"year":2005,"claim":"Two studies delineated a neurite outgrowth signaling cascade downstream of Gαo: Gαo promotes Rap1GAPII proteasomal degradation to activate Rap1, then Rap1→Ral→Src→Stat3 and Rac1→JNK→Stat3 drive neuritogenesis.","evidence":"Co-IP, proteasomal inhibitors, siRNA, dominant-negative/constitutively-active mutant epistasis in Neuro-2A cells","pmids":["15657046","16046413"],"confidence":"High","gaps":["Whether this cascade operates in primary neurons in vivo not confirmed","Direct Gαo–Rap1GAPII binding domain not mapped"]},{"year":2008,"claim":"Gαo was placed into the non-canonical Wnt-JNK/planar cell polarity pathway, coupling Wnt3a to RhoA/Rac1/Cdc42 through Dishevelled-1/3, independently of Gαq and canonical β-catenin signaling.","evidence":"Systematic epistasis with dominant-negatives, shRNA, and Rho GTPase activation assays in F9 teratocarcinoma cells","pmids":["18187455"],"confidence":"High","gaps":["Frizzled receptor identity upstream of Gαo not defined","In vivo PCP phenotype in Gnao1 mutants not demonstrated"]},{"year":2011,"claim":"Conditional Gαo deletion in vomeronasal neurons abolished electrophysiological responses to V2R ligands and eliminated territorial aggression, proving Gαo is the obligate transducer for this sensory modality; separately, the oncogenic R243H mutation was shown to constitutively activate Gαo by accelerating nucleotide exchange via disruption of a conserved R243-E43 salt bridge.","evidence":"Cre-loxP conditional KO with calcium imaging and behavioral assays; in vitro GTPase/exchange assays with mutagenesis and NIH-3T3 transformation","pmids":["21768373","21317923"],"confidence":"High","gaps":["Whether all V2R-class ligands require Gαo not tested","R243H oncogenic pathway in human tumors not characterized"]},{"year":2013,"claim":"De novo GNAO1 mutations were identified as a cause of epileptic encephalopathy; functional assays showed that destabilizing mutations impair plasma membrane localization while switch-II mutations impair GTP binding, both reducing Gαo-mediated Ca²⁺ channel inhibition.","evidence":"Whole-exome sequencing of affected children, transient expression with immunofluorescence and electrophysiology","pmids":["23993195"],"confidence":"High","gaps":["Genotype-phenotype correlation across full mutational spectrum not yet systematic","Neuronal circuit-level mechanism of seizures not addressed"]},{"year":2014,"claim":"An RGS-insensitive Gαo knock-in (G184S) produced seizures and strain-dependent lethality, demonstrating that failure to terminate Gαo signaling suffices to cause epileptic encephalopathy.","evidence":"Genomic knock-in mouse with EEG recording and PTZ kindling","pmids":["24700286"],"confidence":"High","gaps":["Specific RGS proteins responsible for Gαo turnoff in seizure-relevant circuits not identified","Whether human RGS-resistance mutations exist not established at this time"]},{"year":2017,"claim":"Systematic functional classification of 15 GNAO1 clinical variants established that loss-of-function mutations associate with epileptic encephalopathy and gain-of-function mutations with movement disorders, providing a molecular framework for genotype-phenotype correlation.","evidence":"cAMP inhibition assay with co-expressed α2A-adrenergic receptor in HEK-293T cells","pmids":["28747448"],"confidence":"High","gaps":["cAMP is only one effector readout; other downstream pathways not tested","Mixed phenotype patients not fully explained"]},{"year":2022,"claim":"Biochemical dissection of encephalopathy hotspot mutations (Gly203, Arg209, Glu246) revealed accelerated GTP uptake coupled with catalytic-residue (Gln205) displacement blocking hydrolysis, and Zn²⁺ was identified as a pharmacological corrector restoring GTPase activity; in parallel, C. elegans and mouse models confirmed dominant-negative activity of multiple pathological alleles.","evidence":"In vitro GTPase/exchange assays, Drosophila rescue, CRISPR knock-in in C. elegans and mouse with behavioral assays","pmids":["36206333","34508586"],"confidence":"High","gaps":["Zn²⁺ therapeutic window and CNS delivery not addressed","Dominant-negative mechanism (e.g. Gβγ sequestration vs. effector titration) not resolved"]},{"year":2024,"claim":"A comprehensive survey of >80 pathological Gαo variants uncovered neomorphic interactions with Ric8A and especially Ric8B chaperones (normally Gαs/olf-specific), which relocalize to the Golgi and correlate with disease severity — establishing chaperone sequestration as a disease-driving mechanism distinct from simple loss or gain of canonical function.","evidence":"Systematic co-IP and immunofluorescence across >80 variants","pmids":["38874642"],"confidence":"High","gaps":["Whether Ric8B sequestration disrupts Gαs/olf signaling in patient neurons not directly tested","Structural basis of neomorphic Ric8B binding not determined"]},{"year":2024,"claim":"Additional 2024 studies expanded the mechanistic spectrum: N-terminal Leu→Pro mutations uniquely block heterotrimer formation and GPCR coupling (associated with parkinsonism); Gαo regulates Rho GTPase-dependent cytoskeletal remodeling in developing neurons rescuable by ROCK inhibition; and Schwann cell-expressed Gαo negatively regulates myelination via cAMP/PI3K-AKT suppression.","evidence":"Biochemical heterotrimer assays; patient iPSC-derived neurons with ROCK inhibitor rescue; SC-specific conditional KO and overexpression mice with nerve injury remyelination","pmids":["38358016","39048611","38331815"],"confidence":"High","gaps":["Whether ROCK inhibitors have therapeutic potential for GNAO1 encephalopathy in vivo unknown","Receptor(s) upstream of Gαo in Schwann cells not identified","Parkinsonism phenotype documented in only two families"]},{"year":null,"claim":"Key unresolved questions include the structural basis of Gαo interactions with effectors and Ric8 chaperones, the identity of the specific neuronal circuits whose dysfunction produces seizures versus movement disorders, whether Zn²⁺ or ROCK inhibitors can be developed as therapeutics, and the in vivo relevance of the Rap1/Stat3 neurite outgrowth pathway.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of Gαo in complex with any effector or Ric8","Circuit-level mechanisms linking Gαo dysfunction to seizures vs. dyskinesia unknown","No clinical trial data for any GNAO1-targeted therapy"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[1,9,13,20,22,33]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2,3,4,8,10]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,6,11,25,29]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,10,22,26]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[22,23]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[23]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,3,5,6,7,8,9,18]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[3,10,11,19,27,35]},{"term_id":"R-HSA-9709957","term_label":"Sensory Perception","supporting_discovery_ids":[0,2,8,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,27,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,17,18,20,21,23]}],"complexes":["Heterotrimeric Go (Gαo/Gβγ)"],"partners":["CACNA1A","GRM6","RAP1GAP2","DVL1","DVL3","RIC8A","RIC8B","SPTAN1"],"other_free_text":[]},"mechanistic_narrative":"GNAO1 encodes Gαo, the most abundant heterotrimeric G protein α-subunit in the mammalian nervous system, which couples diverse GPCRs to downstream effectors governing neuronal excitability, sensory transduction, neurite outgrowth, and myelination. Gαo inhibits N-type and L-type voltage-gated Ca²⁺ channels through both direct interaction with the α1A (Cav2.1) subunit and Gβγ release [PMID:7932231, PMID:11395521, PMID:9050846], is the obligate transducer of the mGluR6 cascade in retinal ON bipolar cells [PMID:11124982] and of V2R-mediated pheromone signaling in vomeronasal neurons [PMID:21768373], and drives neurite outgrowth via Rap1→Ral→Src→Stat3 and RhoA/Rac1/Cdc42 signaling downstream of cannabinoid and Wnt receptors [PMID:15657046, PMID:16046413, PMID:18187455]. De novo GNAO1 mutations cause childhood-onset neurological disease: loss-of-function alleles that impair GTP binding or plasma membrane localization produce epileptic encephalopathy, whereas gain-of-function alleles with accelerated GTP uptake or resistance to RGS-mediated GTPase acceleration primarily cause hyperkinetic movement disorders, and neomorphic interactions of mutant Gαo with Ric8A/B chaperones contribute to disease dominance [PMID:23993195, PMID:28747448, PMID:36206333, PMID:38874642]."},"prefetch_data":{"uniprot":{"accession":"P09471","full_name":"Guanine nucleotide-binding protein G(o) subunit alpha","aliases":[],"length_aa":354,"mass_kda":40.1,"function":"Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:29925951, PubMed:33408414). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (By similarity). Signaling by an activated GPCR promotes GDP release and GTP binding (By similarity). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (By similarity). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (By similarity). Signaling is mediated via effector proteins, such as adenylate cyclase (By similarity). Inhibits adenylate cyclase activity, leading to decreased intracellular cAMP levels (By similarity)","subcellular_location":"Cell membrane; Membrane","url":"https://www.uniprot.org/uniprotkb/P09471/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GNAO1","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GNAO1","total_profiled":1310},"omim":[{"mim_id":"619344","title":"PURKINJE CELL PROTEIN 2; PCP2","url":"https://www.omim.org/entry/619344"},{"mim_id":"617493","title":"NEURODEVELOPMENTAL DISORDER WITH INVOLUNTARY MOVEMENTS; NEDIM","url":"https://www.omim.org/entry/617493"},{"mim_id":"617098","title":"RIBONUCLEASE K; RNASEK","url":"https://www.omim.org/entry/617098"},{"mim_id":"615473","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 17; DEE17","url":"https://www.omim.org/entry/615473"},{"mim_id":"611240","title":"GPRIN FAMILY, MEMBER 2; GPRIN2","url":"https://www.omim.org/entry/611240"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":133.2},{"tissue":"retina","ntpm":48.0}],"url":"https://www.proteinatlas.org/search/GNAO1"},"hgnc":{"alias_symbol":["G-ALPHA-o"],"prev_symbol":[]},"alphafold":{"accession":"P09471","domains":[{"cath_id":"3.40.50.300","chopping":"37-60_182-191_199-338","consensus_level":"high","plddt":96.3627,"start":37,"end":338},{"cath_id":"1.10.400.10","chopping":"62-169","consensus_level":"high","plddt":97.5153,"start":62,"end":169}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09471","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09471-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09471-F1-predicted_aligned_error_v6.png","plddt_mean":94.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GNAO1","jax_strain_url":"https://www.jax.org/strain/search?query=GNAO1"},"sequence":{"accession":"P09471","fasta_url":"https://rest.uniprot.org/uniprotkb/P09471.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09471/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09471"}},"corpus_meta":[{"pmid":"8558259","id":"PMC_8558259","title":"Sensory transduction in vomeronasal neurons: evidence for G alpha o, G alpha i2, and adenylyl cyclase II as major components of a pheromone signaling cascade.","date":"1996","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/8558259","citation_count":253,"is_preprint":false},{"pmid":"11100733","id":"PMC_11100733","title":"G alpha(i) and G alpha(o) are target proteins of reactive oxygen species.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11100733","citation_count":220,"is_preprint":false},{"pmid":"23993195","id":"PMC_23993195","title":"De Novo mutations in GNAO1, encoding a Gαo subunit of heterotrimeric G proteins, cause epileptic encephalopathy.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23993195","citation_count":189,"is_preprint":false},{"pmid":"11124982","id":"PMC_11124982","title":"The light response of ON bipolar neurons requires G[alpha]o.","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11124982","citation_count":164,"is_preprint":false},{"pmid":"21768373","id":"PMC_21768373","title":"G protein G(alpha)o is essential for vomeronasal function and aggressive behavior in mice.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21768373","citation_count":146,"is_preprint":false},{"pmid":"7932231","id":"PMC_7932231","title":"Muscarinic M-current inhibition via G alpha q/11 and alpha-adrenoceptor inhibition of Ca2+ current via G alpha o in rat sympathetic neurones.","date":"1994","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7932231","citation_count":130,"is_preprint":false},{"pmid":"9050846","id":"PMC_9050846","title":"G alpha(o) is necessary for muscarinic regulation of Ca2+ channels in mouse heart.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9050846","citation_count":113,"is_preprint":false},{"pmid":"15657046","id":"PMC_15657046","title":"Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15657046","citation_count":107,"is_preprint":false},{"pmid":"12454992","id":"PMC_12454992","title":"G protein subunit G gamma 13 is coexpressed with G alpha o, G beta 3, and G beta 4 in retinal ON bipolar cells.","date":"2003","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12454992","citation_count":105,"is_preprint":false},{"pmid":"28747448","id":"PMC_28747448","title":"Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations.","date":"2017","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28747448","citation_count":92,"is_preprint":false},{"pmid":"16046413","id":"PMC_16046413","title":"The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16046413","citation_count":92,"is_preprint":false},{"pmid":"12642378","id":"PMC_12642378","title":"Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity.","date":"2003","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12642378","citation_count":75,"is_preprint":false},{"pmid":"18187455","id":"PMC_18187455","title":"G alpha o mediates WNT-JNK signaling through dishevelled 1 and 3, RhoA family members, and MEKK 1 and 4 in mammalian cells.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18187455","citation_count":70,"is_preprint":false},{"pmid":"30103967","id":"PMC_30103967","title":"Deep brain stimulation is effective in pediatric patients with GNAO1 associated severe hyperkinesia.","date":"2018","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30103967","citation_count":62,"is_preprint":false},{"pmid":"29758257","id":"PMC_29758257","title":"A mechanistic review on GNAO1-associated movement disorder.","date":"2018","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29758257","citation_count":60,"is_preprint":false},{"pmid":"30682224","id":"PMC_30682224","title":"Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphate-binding region.","date":"2019","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/30682224","citation_count":57,"is_preprint":false},{"pmid":"26060304","id":"PMC_26060304","title":"Progressive Movement Disorder in Brothers Carrying a GNAO1 Mutation Responsive to Deep Brain Stimulation.","date":"2015","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26060304","citation_count":57,"is_preprint":false},{"pmid":"21317923","id":"PMC_21317923","title":"Molecular basis of a novel oncogenic mutation in GNAO1.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21317923","citation_count":55,"is_preprint":false},{"pmid":"35722775","id":"PMC_35722775","title":"Highlighting the Dystonic Phenotype Related to GNAO1.","date":"2022","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/35722775","citation_count":52,"is_preprint":false},{"pmid":"10693938","id":"PMC_10693938","title":"Immunoprecipitation of high-affinity, guanine nucleotide-sensitive, solubilized mu-opioid receptors from rat brain: coimmunoprecipitation of the G proteins G(alpha o), G(alpha i1), and G(alpha i3).","date":"2000","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10693938","citation_count":47,"is_preprint":false},{"pmid":"9654151","id":"PMC_9654151","title":"Human substance P receptor expressed in Chinese hamster ovary cells directly activates G(alpha q/11), G(alpha s), G(alpha o).","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9654151","citation_count":44,"is_preprint":false},{"pmid":"7544301","id":"PMC_7544301","title":"Voltage-dependent calcium channel beta-subunits in combination with alpha 1 subunits, have a GTPase activating effect to promote the hydrolysis of GTP by G alpha o in rat frontal cortex.","date":"1995","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7544301","citation_count":44,"is_preprint":false},{"pmid":"36206333","id":"PMC_36206333","title":"Restoration of the GTPase activity and cellular interactions of Gαo mutants by Zn2+ in GNAO1 encephalopathy models.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36206333","citation_count":41,"is_preprint":false},{"pmid":"27625011","id":"PMC_27625011","title":"Recurrent GNAO1 Mutations Associated With Developmental Delay and a Movement Disorder.","date":"2016","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27625011","citation_count":40,"is_preprint":false},{"pmid":"7727415","id":"PMC_7727415","title":"Interactions between the amino- and carboxyl-terminal regions of G alpha subunits: analysis of mutated G alpha o/G alpha i2 chimeras.","date":"1995","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7727415","citation_count":39,"is_preprint":false},{"pmid":"30987631","id":"PMC_30987631","title":"Genes CEP55, FOXD3, FOXF2, GNAO1, GRIA4, and KCNA5 as potential diagnostic biomarkers in colorectal cancer.","date":"2019","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/30987631","citation_count":38,"is_preprint":false},{"pmid":"9415716","id":"PMC_9415716","title":"Role of G alpha q or G alpha o proteins in alpha 1-adrenoceptor subtype-mediated responses in Fischer 344 rat aorta.","date":"1997","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9415716","citation_count":38,"is_preprint":false},{"pmid":"34622282","id":"PMC_34622282","title":"Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34622282","citation_count":37,"is_preprint":false},{"pmid":"12354761","id":"PMC_12354761","title":"An N-terminal region of Caenorhabditis elegans RGS proteins EGL-10 and EAT-16 directs inhibition of G(alpha)o versus G(alpha)q signaling.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12354761","citation_count":36,"is_preprint":false},{"pmid":"24700286","id":"PMC_24700286","title":"Gain-of-function mutation in Gnao1: a murine model of epileptiform encephalopathy (EIEE17)?","date":"2014","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/24700286","citation_count":35,"is_preprint":false},{"pmid":"37548038","id":"PMC_37548038","title":"Severity of GNAO1-Related Disorder Correlates with Changes in G-Protein Function.","date":"2023","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37548038","citation_count":34,"is_preprint":false},{"pmid":"27072799","id":"PMC_27072799","title":"GNAO1 encephalopathy: further delineation of a severe neurodevelopmental syndrome affecting females.","date":"2016","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27072799","citation_count":34,"is_preprint":false},{"pmid":"33107105","id":"PMC_33107105","title":"GNAO1 organizes the cytoskeletal remodeling and firing of developing neurons.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33107105","citation_count":32,"is_preprint":false},{"pmid":"35090564","id":"PMC_35090564","title":"Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation.","date":"2022","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/35090564","citation_count":32,"is_preprint":false},{"pmid":"28202424","id":"PMC_28202424","title":"GNAO1-associated epileptic encephalopathy and movement disorders: c.607G>A variant represents a probable mutation hotspot with a distinct phenotype.","date":"2017","source":"Epileptic disorders : international epilepsy journal with videotape","url":"https://pubmed.ncbi.nlm.nih.gov/28202424","citation_count":32,"is_preprint":false},{"pmid":"2118945","id":"PMC_2118945","title":"Pretreatment of mouse striatal neurons in primary culture with 17 beta-estradiol enhances the pertussis toxin-catalyzed ADP-ribosylation of G alpha o,i protein subunits.","date":"1990","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2118945","citation_count":32,"is_preprint":false},{"pmid":"31076915","id":"PMC_31076915","title":"Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation.","date":"2019","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/31076915","citation_count":31,"is_preprint":false},{"pmid":"29661126","id":"PMC_29661126","title":"GNAO1 Mutation-Induced Pediatric Dystonic Storm Rescue With Pallidal Deep Brain Stimulation.","date":"2018","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29661126","citation_count":30,"is_preprint":false},{"pmid":"8458398","id":"PMC_8458398","title":"In situ hybridization reveals specific increases in G alpha s and G alpha o mRNA in discrete brain regions of morphine-tolerant rats.","date":"1993","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8458398","citation_count":30,"is_preprint":false},{"pmid":"34508586","id":"PMC_34508586","title":"Genetic modeling of GNAO1 disorder delineates mechanisms of Gαo dysfunction.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34508586","citation_count":29,"is_preprint":false},{"pmid":"34685729","id":"PMC_34685729","title":"Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34685729","citation_count":27,"is_preprint":false},{"pmid":"26485252","id":"PMC_26485252","title":"Clinical whole-exome sequencing reveals a novel missense pathogenic variant of GNAO1 in a patient with infantile-onset epilepsy.","date":"2015","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26485252","citation_count":27,"is_preprint":false},{"pmid":"31907305","id":"PMC_31907305","title":"Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone.","date":"2020","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31907305","citation_count":25,"is_preprint":false},{"pmid":"27916449","id":"PMC_27916449","title":"A case of severe movement disorder with GNAO1 mutation responsive to topiramate.","date":"2017","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/27916449","citation_count":24,"is_preprint":false},{"pmid":"2506013","id":"PMC_2506013","title":"Purification and characterization of subforms of the guanine-nucleotide-binding proteins G alpha i and G alpha o.","date":"1989","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2506013","citation_count":24,"is_preprint":false},{"pmid":"32898863","id":"PMC_32898863","title":"Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32898863","citation_count":21,"is_preprint":false},{"pmid":"11395521","id":"PMC_11395521","title":"Binding of G alpha(o) N terminus is responsible for the voltage-resistant inhibition of alpha(1A) (P/Q-type, Ca(v)2.1) Ca(2+) channels.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11395521","citation_count":21,"is_preprint":false},{"pmid":"28503590","id":"PMC_28503590","title":"Clinical Phenotype of De Novo GNAO1 Mutation: Case Report and Review of Literature.","date":"2015","source":"Child neurology open","url":"https://pubmed.ncbi.nlm.nih.gov/28503590","citation_count":20,"is_preprint":false},{"pmid":"33036271","id":"PMC_33036271","title":"Humanization of Drosophila Gαo to Model GNAO1 Paediatric Encephalopathies.","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/33036271","citation_count":20,"is_preprint":false},{"pmid":"19460419","id":"PMC_19460419","title":"Gnao1 (G alphaO protein) is a likely genetic contributor to variation in physical dependence on opioids in mice.","date":"2009","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19460419","citation_count":19,"is_preprint":false},{"pmid":"23984917","id":"PMC_23984917","title":"The down-regulation of GNAO1 and its promoting role in hepatocellular carcinoma.","date":"2013","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/23984917","citation_count":18,"is_preprint":false},{"pmid":"34122306","id":"PMC_34122306","title":"Phenotypes of GNAO1 Variants in a Chinese Cohort.","date":"2021","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34122306","citation_count":18,"is_preprint":false},{"pmid":"38903163","id":"PMC_38903163","title":"Dyskinetic crisis in GNAO1-related disorders: clinical perspectives and management strategies.","date":"2024","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38903163","citation_count":17,"is_preprint":false},{"pmid":"9606722","id":"PMC_9606722","title":"Inactivation of the G alpha i2 and G alpha o genes by homologous recombination.","date":"1997","source":"Receptors & channels","url":"https://pubmed.ncbi.nlm.nih.gov/9606722","citation_count":17,"is_preprint":false},{"pmid":"7493405","id":"PMC_7493405","title":"Developmental expression of G alpha o and G alpha s isoforms in PC12 cells: relationship to neurite outgrowth.","date":"1995","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/7493405","citation_count":17,"is_preprint":false},{"pmid":"38874642","id":"PMC_38874642","title":"Neomorphic Gαo mutations gain interaction with Ric8 proteins in GNAO1 encephalopathies.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38874642","citation_count":16,"is_preprint":false},{"pmid":"36833246","id":"PMC_36833246","title":"Phenotypic Assessment of Pathogenic Variants in GNAO1 and Response to Caffeine in C. elegans Models of the Disease.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36833246","citation_count":16,"is_preprint":false},{"pmid":"40225165","id":"PMC_40225165","title":"Phenotypic Diversity in GNAO1 Patients: A Comprehensive Overview of Variants and Phenotypes.","date":"2023","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/40225165","citation_count":15,"is_preprint":false},{"pmid":"38881224","id":"PMC_38881224","title":"Clinical and Molecular Profiling in GNAO1 Permits Phenotype-Genotype Correlation.","date":"2024","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/38881224","citation_count":14,"is_preprint":false},{"pmid":"30682176","id":"PMC_30682176","title":"Mouse models of GNAO1-associated movement disorder: Allele- and sex-specific differences in phenotypes.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30682176","citation_count":14,"is_preprint":false},{"pmid":"24549219","id":"PMC_24549219","title":"Comprehensive pathway-based analysis identifies associations of BCL2, GNAO1 and CHD2 with non-obstructive azoospermia risk.","date":"2014","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24549219","citation_count":14,"is_preprint":false},{"pmid":"27515449","id":"PMC_27515449","title":"Toll-like receptor 2-mediated MAPKs and NF-κB activation requires the GNAO1-dependent pathway in human mast cells.","date":"2016","source":"Integrative biology : quantitative biosciences from nano to macro","url":"https://pubmed.ncbi.nlm.nih.gov/27515449","citation_count":14,"is_preprint":false},{"pmid":"38434323","id":"PMC_38434323","title":"Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38434323","citation_count":13,"is_preprint":false},{"pmid":"39153472","id":"PMC_39153472","title":"Zinc for GNAO1 encephalopathy: Preclinical profiling and a clinical case.","date":"2024","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/39153472","citation_count":13,"is_preprint":false},{"pmid":"29709639","id":"PMC_29709639","title":"DNMT1 mediated promoter methylation of GNAO1 in hepatoma carcinoma cells.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29709639","citation_count":13,"is_preprint":false},{"pmid":"34875852","id":"PMC_34875852","title":"NRSF-GNAO1 Pathway Contributes to the Regulation of Cardiac Ca2+ Homeostasis.","date":"2021","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/34875852","citation_count":12,"is_preprint":false},{"pmid":"37999699","id":"PMC_37999699","title":"Deep Brain Stimulation for GNAO1-Associated Dystonia: A Systematic Review and Meta-Analysis.","date":"2023","source":"Neuromodulation : journal of the International Neuromodulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/37999699","citation_count":12,"is_preprint":false},{"pmid":"35080448","id":"PMC_35080448","title":"Mice with monoallelic GNAO1 loss exhibit reduced inhibitory synaptic input to cerebellar Purkinje cells.","date":"2022","source":"Journal of neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/35080448","citation_count":12,"is_preprint":false},{"pmid":"37001522","id":"PMC_37001522","title":"In-depth molecular profiling of an intronic GNAO1 mutant as the basis for personalized high-throughput drug screening.","date":"2023","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37001522","citation_count":12,"is_preprint":false},{"pmid":"34441836","id":"PMC_34441836","title":"Cognitive Assessment in GNAO1 Neurodevelopmental Disorder Using an Eye Tracking System.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34441836","citation_count":12,"is_preprint":false},{"pmid":"2512386","id":"PMC_2512386","title":"Distribution of the alpha-subunit of the guanine nucleotide-binding protein Gi2 and its comparison to G alpha o.","date":"1989","source":"Journal of receptor research","url":"https://pubmed.ncbi.nlm.nih.gov/2512386","citation_count":11,"is_preprint":false},{"pmid":"29935962","id":"PMC_29935962","title":"A patient with a GNAO1 mutation with decreased spontaneous movements, hypotonia, and dystonic features.","date":"2018","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/29935962","citation_count":10,"is_preprint":false},{"pmid":"33358199","id":"PMC_33358199","title":"GNAO1 mutation-related severe involuntary movements treated with gabapentin.","date":"2020","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/33358199","citation_count":10,"is_preprint":false},{"pmid":"18192223","id":"PMC_18192223","title":"Enhanced calcium cycling and contractile function in transgenic hearts expressing constitutively active G alpha o* protein.","date":"2008","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18192223","citation_count":10,"is_preprint":false},{"pmid":"37887313","id":"PMC_37887313","title":"Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37887313","citation_count":9,"is_preprint":false},{"pmid":"35147852","id":"PMC_35147852","title":"An intronic GNAO1 variant leading to in-frame insertion cause movement disorder controlled by deep brain stimulation.","date":"2022","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/35147852","citation_count":9,"is_preprint":false},{"pmid":"29961512","id":"PMC_29961512","title":"Neonatal epileptic encephalopathy caused by de novo GNAO1 mutation misdiagnosed as atypical Rett syndrome: Cautions in interpretation of genomic test results.","date":"2017","source":"Seminars in pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29961512","citation_count":9,"is_preprint":false},{"pmid":"38358016","id":"PMC_38358016","title":"GNAO1 Mutations Affecting the N-Terminal α-Helix of Gαo Lead to Parkinsonism.","date":"2024","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/38358016","citation_count":8,"is_preprint":false},{"pmid":"36247896","id":"PMC_36247896","title":"Treating GNAO1 mutation-related severe movement disorders with oxcarbazepine: a case report.","date":"2022","source":"Translational pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/36247896","citation_count":8,"is_preprint":false},{"pmid":"35509770","id":"PMC_35509770","title":"Both subthalamic and pallidal deep brain stimulation are effective for GNAO1-associated dystonia: three case reports and a literature review.","date":"2022","source":"Therapeutic advances in neurological disorders","url":"https://pubmed.ncbi.nlm.nih.gov/35509770","citation_count":8,"is_preprint":false},{"pmid":"35117701","id":"PMC_35117701","title":"BRD9 controls the oxytocin signaling pathway in gastric cancer via CANA2D4, CALML6, GNAO1, and KCNJ5.","date":"2020","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35117701","citation_count":7,"is_preprint":false},{"pmid":"37077890","id":"PMC_37077890","title":"CRISPR/Cas9-generated mouse model with humanizing single-base substitution in the Gnao1 for safety studies of RNA therapeutics.","date":"2023","source":"Frontiers in genome editing","url":"https://pubmed.ncbi.nlm.nih.gov/37077890","citation_count":7,"is_preprint":false},{"pmid":"36654732","id":"PMC_36654732","title":"GNAO1-related neurodevelopmental disorder: Literature review and caregiver survey.","date":"2022","source":"Epilepsy & behavior reports","url":"https://pubmed.ncbi.nlm.nih.gov/36654732","citation_count":6,"is_preprint":false},{"pmid":"39048611","id":"PMC_39048611","title":"Gnao1 is a molecular switch that regulates the Rho signaling pathway in differentiating neurons.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39048611","citation_count":6,"is_preprint":false},{"pmid":"39897576","id":"PMC_39897576","title":"Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder.","date":"2024","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/39897576","citation_count":5,"is_preprint":false},{"pmid":"35964317","id":"PMC_35964317","title":"[Effective Viral Delivery of Genetic Constructs to Neuronal Culture for Modeling and Gene Therapy of GNAO1 Encephalopathy].","date":"2022","source":"Molekuliarnaia biologiia","url":"https://pubmed.ncbi.nlm.nih.gov/35964317","citation_count":5,"is_preprint":false},{"pmid":"35855141","id":"PMC_35855141","title":"Deep brain stimulation in a young child with GNAO1 mutation - Feasible and helpful.","date":"2022","source":"Surgical neurology international","url":"https://pubmed.ncbi.nlm.nih.gov/35855141","citation_count":5,"is_preprint":false},{"pmid":"34900204","id":"PMC_34900204","title":"GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma.","date":"2021","source":"Journal of healthcare engineering","url":"https://pubmed.ncbi.nlm.nih.gov/34900204","citation_count":5,"is_preprint":false},{"pmid":"35725943","id":"PMC_35725943","title":"DBS emergency surgery for treatment of dystonic storm associated with rhabdomyolysis and acute colitis in DYT-GNAO1.","date":"2022","source":"Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/35725943","citation_count":5,"is_preprint":false},{"pmid":"36980817","id":"PMC_36980817","title":"Visual Function in Children with GNAO1-Related Encephalopathy.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36980817","citation_count":4,"is_preprint":false},{"pmid":"38215303","id":"PMC_38215303","title":"RNA Interference Effectors Selectively Silence the Pathogenic Variant GNAO1 c.607 G > A In Vitro.","date":"2024","source":"Nucleic acid therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38215303","citation_count":4,"is_preprint":false},{"pmid":"37705601","id":"PMC_37705601","title":"Phenotypes in children with GNAO1 encephalopathy in China.","date":"2023","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/37705601","citation_count":4,"is_preprint":false},{"pmid":"8897310","id":"PMC_8897310","title":"ADP-ribosylation of G alpha i and G alpha o in pituitary cells enhances their recognition by antibodies directed against their carboxyl termini.","date":"1996","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/8897310","citation_count":4,"is_preprint":false},{"pmid":"11562427","id":"PMC_11562427","title":"Reciprocal modulation of alpha(2A)-adrenoceptor and G(alpha o) protein states as determined by carboxy-terminal mutagenesis of a G(alpha o) protein.","date":"2001","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11562427","citation_count":4,"is_preprint":false},{"pmid":"39580518","id":"PMC_39580518","title":"GNAO1 overexpression promotes neural differentiation of glioma stem-like cells and reduces tumorigenicity through TRIM21/CREB/HES1 axis.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39580518","citation_count":3,"is_preprint":false},{"pmid":"37034444","id":"PMC_37034444","title":"Dystonic Cerebral Palsy Phenotype Due to GNAO1 Variant Responsive to Levodopa.","date":"2023","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37034444","citation_count":3,"is_preprint":false},{"pmid":"38331815","id":"PMC_38331815","title":"The Schwann cell-specific G-protein Gαo (Gnao1) is a cell-intrinsic controller contributing to the regulation of myelination in peripheral nerve system.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/38331815","citation_count":3,"is_preprint":false},{"pmid":"9759923","id":"PMC_9759923","title":"Quantification of human dopamine D2s receptor interactions with G alpha(i,1,2)- and G alpha(o)-proteins.","date":"1998","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/9759923","citation_count":3,"is_preprint":false},{"pmid":"38106673","id":"PMC_38106673","title":"Gln52 mutations in GNAO1-related disorders and personalized drug discovery.","date":"2023","source":"Epilepsy & behavior reports","url":"https://pubmed.ncbi.nlm.nih.gov/38106673","citation_count":2,"is_preprint":false},{"pmid":"35782616","id":"PMC_35782616","title":"Gonadal mosaicism in GNAO1 causing neurodevelopmental disorder with involuntary movements; two additional variants.","date":"2022","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/35782616","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48786,"output_tokens":8346,"usd":0.135774},"stage2":{"model":"claude-opus-4-6","input_tokens":12541,"output_tokens":4260,"usd":0.253808},"total_usd":0.389582,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Gαo and Gαi2 are expressed in distinct subsets of vomeronasal sensory neurons and are enriched in VNO microvilli, indicating roles in pheromone sensory transduction via separate G-protein-coupled cascades alongside adenylyl cyclase type II.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, cDNA cloning\",\n      \"journal\": \"The Journal of Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization with functional inference but no direct reconstitution; replicated across methods in same study\",\n      \"pmids\": [\"8558259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"H2O2 directly activates purified heterotrimeric Go (but not Gs) in vitro by modifying Gαo, leading to subunit dissociation and subsequent Gβγ-dependent ERK activation, identifying Gαo as a direct target of reactive oxygen species.\",\n      \"method\": \"In vitro [35S]GTPγS binding assay with purified proteins, cardiomyocyte cell experiments, Gβγ inhibition\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified proteins plus mutagenesis/inhibitor controls; strong evidence\",\n      \"pmids\": [\"11100733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Gαo is required for the light response of ON bipolar neurons: mice lacking Gαo show complete absence of the b-wave of the ERG while rod/cone photocurrents (a-wave) and retinal architecture are normal, establishing Gαo as the essential G protein in the mGluR6 cascade.\",\n      \"method\": \"Knockout mouse (Gαo−/−), electroretinography\",\n      \"journal\": \"The Journal of Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic knockout with specific physiological phenotype; replicated across rod- and cone-driven components\",\n      \"pmids\": [\"11124982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Intraneuronal antibody microinjection established that Gαo (not Gαq/11) mediates α-adrenoceptor inhibition of N/L-type Ca2+ current in sympathetic neurons, while Gαq/11 mediates muscarinic inhibition of M-current.\",\n      \"method\": \"Intracellular antibody microinjection in SCG neurons, patch-clamp electrophysiology\",\n      \"journal\": \"The Journal of Physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — selective antibody microinjection with electrophysiological readout; highly cited foundational study\",\n      \"pmids\": [\"7932231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Gαo is required for muscarinic inhibition of L-type Ca2+ channels in ventricular myocytes; Gαo−/− mice show no muscarinic inhibition of L-type Ca2+ current while isoproterenol responses and muscarinic regulation of atrial K+ channels remain normal.\",\n      \"method\": \"Homologous recombination knockout mouse, whole-cell patch clamp in ventricular myocytes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with specific electrophysiological readout; two independent phenotypes tested\",\n      \"pmids\": [\"9050846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Gαo/i directly interacts with Rap1GAPII and promotes its ubiquitination and proteasomal degradation, thereby activating Rap1 and inducing neurite outgrowth downstream of the CB1 cannabinoid receptor in Neuro-2A cells.\",\n      \"method\": \"Co-immunoprecipitation, proteasomal inhibitor (lactacystin), siRNA, dominant-negative constructs, pertussis toxin\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (protein interaction, genetic, pharmacological) in same study\",\n      \"pmids\": [\"15657046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Gαo/i-coupled CB1 receptor sequentially activates Rap1→Ral→Src→Stat3 and also Rac1→JNK→Stat3 pathways for neurite outgrowth; Src activation requires both Rap1 and Ral downstream of Gαo.\",\n      \"method\": \"Dominant-negative and constitutively active mutant overexpression, pharmacological inhibitors, phosphorylation assays in Neuro-2A cells\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by multiple dominant-negative constructs and pharmacological inhibitors; strong within-study evidence\",\n      \"pmids\": [\"16046413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Gαo mediates WNT3a-JNK (planar cell polarity) signaling in mammalian F9 cells through Dishevelled-1 and Dishevelled-3 (but not Dvl-2), RhoA/Rac1/Cdc42, and MEKK1/MEKK4, independently of Gαq; Gαo is not required for canonical WNT-β-catenin signaling alone.\",\n      \"method\": \"Epistasis with dominant-negative/shRNA, Dapper1 antagonist, chemical inhibitors, RhoA/Rac1/Cdc42 activation assays in mouse F9 teratocarcinoma cells\",\n      \"journal\": \"Journal of Cell Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic epistasis with multiple orthogonal genetic and pharmacological tools\",\n      \"pmids\": [\"18187455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Conditional deletion of Gαo in vomeronasal sensory neurons abolishes electrophysiological and Ca2+ responses to MHC class I antigens, major urinary proteins, and N-formylated mitochondrial peptides (V2R neuron ligands), and eliminates male-male and maternal territorial aggression.\",\n      \"method\": \"Cre-loxP conditional knockout, extracellular field recordings, calcium imaging, behavioral tests\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with multiple electrophysiological and behavioral readouts; multiple ligands tested\",\n      \"pmids\": [\"21768373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The oncogenic Gαo R243H mutation accelerates guanine nucleotide exchange (constitutive activation) without impairing GTPase activity or GAP sensitivity; the mechanism involves loss of a conserved R243-E43 electrostatic interaction in the P-loop. Constitutively active Gαo R243H enhances Src-STAT3 signaling to promote cellular transformation.\",\n      \"method\": \"Limited proteolysis, nucleotide-binding assays, single-turnover and steady-state GTPase assays, mutagenesis, NIH-3T3 transformation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple in vitro enzymatic assays with mutagenesis and structural analysis in same study\",\n      \"pmids\": [\"21317923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"De novo GNAO1 mutations cause epileptic encephalopathy; mutations predicted to destabilize the Gα fold impair plasma membrane localization, while the Gly203Arg switch-II mutation impairs GTP binding/downstream effector activation. All four mutants show reduced Gαo-mediated inhibition of calcium currents by norepinephrine.\",\n      \"method\": \"Whole-exome sequencing, transient expression with immunofluorescence localization, electrophysiological calcium current recording, 3D structural modeling\",\n      \"journal\": \"American Journal of Human Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional assays (Ca2+ current electrophysiology, localization) plus structural analysis across multiple mutants\",\n      \"pmids\": [\"23993195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The N-terminus of Gαo directly binds the C-terminus of the α1A (P/Q-type, Cav2.1) Ca2+ channel subunit in vitro, and this interaction mediates voltage-resistant (but not voltage-dependent) inhibition of α1A Ca2+ currents; Gβγ mediates the voltage-dependent component.\",\n      \"method\": \"In vitro binding assay with peptides/antisera, patch-clamp electrophysiology with peptide/antibody dialysis\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding reconstitution with blocking peptides/antibodies and direct electrophysiological functional validation\",\n      \"pmids\": [\"11395521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Voltage-dependent Ca2+ channel β-subunits act as GTPase-activating proteins for Gαo in rat frontal cortex membranes; an anti-β-subunit antiserum and a peptide mimicking the β-subunit binding domain both abolish dihydropyridine agonist-stimulated GTP hydrolysis by Go.\",\n      \"method\": \"GTPase assay in cortical membranes, antibody and peptide inhibition, [3H]dihydropyridine binding\",\n      \"journal\": \"FEBS Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — membrane-based enzymatic assay with antibody and peptide blocking; single study\",\n      \"pmids\": [\"7544301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The C-terminal region and amino-terminal contacts (β-strands 1 and 3) of Gαo determine its characteristic nucleotide binding and conformation properties; C-terminal truncation of 14 residues decreases GDP affinity and reveals a GTP-activated conformation in Gαo but not Gαi2, a difference mapped to hydrophobic residues 11-13 from the C-terminus.\",\n      \"method\": \"In vitro translation, native tryptic proteolysis, chimeric Gαo/Gαi2 protein analysis, nucleotide binding assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and structural correlation\",\n      \"pmids\": [\"7727415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Mu-opioid receptor co-immunoprecipitates with Gαo, Gαi1, and Gαi3 (but not Gαs or Gαq/11) from solubilized rat brain in a GTPγS-sensitive manner, demonstrating direct receptor-G protein coupling.\",\n      \"method\": \"Immunoprecipitation from solubilized rat brain, [3H]DAMGO binding, GTPγS competition\",\n      \"journal\": \"Journal of Neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — co-immunoprecipitation from native tissue; GTPγS sensitivity confirms functional complex\",\n      \"pmids\": [\"10693938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human substance P receptor directly activates Gαq/11, Gαs, and Gαo in CHO cell membranes, as shown by photoaffinity labeling of Gα subunits with [32P]AA-GTP upon receptor stimulation followed by immunoprecipitation.\",\n      \"method\": \"Photoaffinity labeling ([32P]azidoanilido-GTP), immunoprecipitation with subunit-specific antibodies\",\n      \"journal\": \"FEBS Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct covalent labeling of activated Gα subunits in membrane preparations; single study\",\n      \"pmids\": [\"9654151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"G protein subunit Gγ13 is coexpressed with Gαo, Gβ3, and Gβ4 specifically in retinal ON bipolar cell dendrites (not OFF), identifying the specific heterotrimer (Gαo/Gβ3 or Gβ4/Gγ13) mediating ON bipolar phototransduction.\",\n      \"method\": \"Immunohistochemistry, GFP-transgenic mouse single-cell RT-PCR, patch-clamp identification\",\n      \"journal\": \"Journal of Comparative Neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — colocalization at protein level in identified cell types confirmed by single-cell PCR; multiple methods in same study\",\n      \"pmids\": [\"12454992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A gain-of-function knock-in mutation (G184S) preventing RGS-mediated GTPase acceleration in Gαo causes epileptiform discharges, seizures, and strain-dependent lethality in mice, demonstrating that constitutive Gαo activity (failure of turnoff) drives epileptic encephalopathy.\",\n      \"method\": \"Genomic knock-in mouse, EEG recording, pentylenetetrazol kindling, genetic modifier mapping\",\n      \"journal\": \"Mammalian Genome\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined knock-in with mechanistic interpretation (RGS resistance) and specific EEG phenotype\",\n      \"pmids\": [\"24700286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GNAO1 clinical mutations segregate into loss-of-function (reduced cAMP inhibition, associated with epileptic encephalopathy) and gain-of-function (lower EC50 for α2A-AR-mediated cAMP inhibition, including G42R, G203R, E246K; associated with movement disorders), establishing a functional correlation with clinical phenotype.\",\n      \"method\": \"Site-directed mutagenesis, HEK-293T expression, Western blot, cAMP inhibition assay with co-expressed α2A-adrenergic receptor\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — 15 clinical variants systematically tested with functional cAMP assay; strong in vitro mechanistic classification\",\n      \"pmids\": [\"28747448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Co-immunoprecipitation and mass spectrometry identified SPTAN1 (α-II spectrin) as an interacting partner of Gαo; GNAO1 silencing attenuates neurite outgrowth, reduces SPTAN1 and Ankyrin-G expression in brain organoids, and impairs synchronized neuronal firing.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, siRNA knockdown, iPSC-derived brain organoids, calcium imaging\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — MS-based interaction identification with functional follow-up in multiple systems; single lab\",\n      \"pmids\": [\"33107105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The three most common encephalopathy mutations (Gly203, Arg209, Glu246) accelerate GTP uptake and inactivate GTP hydrolysis by displacing Gln205 critical for catalysis, resulting in constitutive GTP binding but failure to adopt the active conformation. Zn2+ restores GTPase activity and cellular interactions of these mutants without affecting wild-type Gαo.\",\n      \"method\": \"In vitro GTPase assay, nucleotide binding assay, protein-protein interaction assay, high-throughput drug screening, Drosophila model\",\n      \"journal\": \"Science Advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple in vitro enzymatic assays, structural analysis, and in vivo rescue in same study\",\n      \"pmids\": [\"36206333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"All tested GNAO1 pathological mutations (G42R, G203R, R209C) result in loss of function in C. elegans goa-1 models and also exhibit dominant-negative effects in heterozygous animals; G42R dominant-negative effects were confirmed in mice impairing motor behaviors.\",\n      \"method\": \"CRISPR/Cas9 knock-in in C. elegans and mouse, behavioral assays, transgenic overexpression\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conserved findings across two animal models with CRISPR alleles and transgenic confirmation\",\n      \"pmids\": [\"34508586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Gln52 mutations in Gαo (Q52P, Q52R) abolish GTP binding and hydrolysis; the mutant proteins are defective in interaction with GDP-loaded and GTP-loaded partner proteins, and show strongly reduced plasma membrane localization with accumulation at non-membrane sites.\",\n      \"method\": \"In vitro GTP binding and hydrolysis assays, co-immunoprecipitation, immunofluorescence localization in mammalian cells\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — enzymatic assays plus protein interaction and localization studies with mutagenesis\",\n      \"pmids\": [\"34685729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GNAO1 encephalopathy mutants gain aberrant neomorphic interactions with both Ric8A and Ric8B chaperones (Ric8B normally handles only Gαs/olf), relocalizing them from cytoplasm to Golgi. This neomorphic Ric8 sequestration imbalances neuronal G protein signaling networks and mediates disease dominance; the strength of Gαo-Ric8B interaction correlates with disease severity.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence colocalization, systematic characterization of >80 pathological Gαo variants for GTP handling and partner binding\",\n      \"journal\": \"The Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic multi-variant characterization with orthogonal protein interaction and localization assays; novel mechanism with strong evidence\",\n      \"pmids\": [\"38874642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GNAO1-encoded Gαo is transcriptionally regulated by NRSF in the heart; increased cardiac Gαo elevates L-type Ca2+ channel surface activity, activates CaMKII signaling, and impairs Ca2+ handling in ventricular myocytes, causing cardiac dysfunction.\",\n      \"method\": \"Cardiac-specific NRSF knockout mice, dominant-negative NRSF mice, cardiac-specific Gnao1 overexpression transgenic mice, Gnao1 genetic knockdown, L-type Ca2+ channel current recording\",\n      \"journal\": \"Circulation Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic mouse models with defined electrophysiological and functional readouts\",\n      \"pmids\": [\"34875852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cardiac-specific expression of constitutively active Gαo1* enhances L-type Ca2+ channel current density, calcium transients, and contractile function, associated with increased phosphorylation of ryanodine receptor and phospholamban via reduced protein phosphatase 1 activity (not PKA).\",\n      \"method\": \"Transgenic mice with cardiac-specific constitutively active Gαo*, whole-cell patch clamp, Ca2+ transient measurement, phosphorylation assays, PP1 activity assay\",\n      \"journal\": \"American Journal of Physiology – Heart and Circulatory Physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function model with multiple orthogonal mechanistic readouts\",\n      \"pmids\": [\"18192223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Leu→Pro substitutions at positions 13 and 23 (N-terminal α-helix of Gαo) uniquely destabilize the N-terminal α-helix, blocking heterotrimeric G-protein formation and GPCR-mediated activation, without impairing GTPase activity or overall folding; clinically associated with parkinsonism phenotype.\",\n      \"method\": \"Structural and biochemical characterization of mutant Gαo proteins, heterotrimeric complex formation assay, GPCR coupling assay\",\n      \"journal\": \"Movement Disorders\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro biochemical and structural characterization with clear mechanistic distinction from other mutants\",\n      \"pmids\": [\"38358016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Gαo acts as a molecular switch regulating Rho GTPase signaling in developing neurons; GNAO1 knockdown or the G203R mutation disrupts Rho GTPase-dependent actin cytoskeleton remodeling, growth cone formation, and self-organizing neural rosette assembly; Rho kinase inhibitor Y27632 rescues these morphological phenotypes.\",\n      \"method\": \"siRNA knockdown in Neuro2a, iPSC-derived neurons and organoids from GNAO1 G203R patient, phospho-MLC2 immunostaining, ROCK inhibitor rescue\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — patient iPSC model plus pharmacological rescue; single lab\",\n      \"pmids\": [\"39048611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In C. elegans, the N-terminal region of the RGS protein EGL-10 directs selective inhibition of GOA-1 (Gαo) by forming a complex with the GGL/RGS domain and its associated Gβ subunit GPB-2, affecting membrane localization and G protein target selectivity of the RGS domain.\",\n      \"method\": \"C. elegans transgenic epistasis, chimeric RGS protein analysis, co-immunoprecipitation, subcellular fractionation\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis and co-IP in C. elegans ortholog system; functional relevance to mammalian Gαo regulation\",\n      \"pmids\": [\"12354761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Gnao1 expressed in Schwann cells (not neurons) negatively regulates myelination: SC-specific Gnao1 deletion elevates cAMP and activates PI3K/AKT signaling to promote SC differentiation and accelerate re-myelination after nerve injury, while Gnao1 overexpression delays re-myelination.\",\n      \"method\": \"SC-specific Gnao1 conditional knockout and overexpression mice, nerve injury re-myelination assay, cAMP measurement, PI3K/AKT pathway analysis, RNA sequencing\",\n      \"journal\": \"Acta Neuropathologica Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain- and loss-of-function mouse models with defined cellular and molecular readouts\",\n      \"pmids\": [\"38331815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"αo1 protein levels increase during NGF-induced neurite outgrowth in PC12 cells and correlate with neurite length; the αo1/αo2 ratio increases selectively during differentiation, suggesting Gαo isoform-specific involvement in neuritic extension.\",\n      \"method\": \"Western blot with isoform-specific antibodies, morphometric measurement of neurite length during NGF treatment\",\n      \"journal\": \"Developmental Brain Research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — correlational protein expression analysis; no direct functional manipulation\",\n      \"pmids\": [\"7493405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Gnao1 in the locus coeruleus contributes to physical opioid dependence: Gnao1 expression is upregulated in morphine-dependent C57BL/6 but not A/J mice, and antisense knockdown of Gnao1 reduces naloxone-precipitated withdrawal jumping in dependent B6 mice.\",\n      \"method\": \"Quantitative PCR, antisense oligodeoxynucleotide knockdown, naloxone-precipitated withdrawal behavioral assay, QTL mapping\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — antisense knockdown with specific behavioral readout; single study but genetic evidence converges\",\n      \"pmids\": [\"19460419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"An intronic GNAO1 c.724-8G>A mutation creates a novel splice acceptor site inserting Pro-Gln in the switch III region; this misconfigures switch III-switch II interactions, increases GTP uptake, and causes defective GTP hydrolysis and aberrant effector protein interactions, while intracellular localization, Gβγ interactions, and GPCR coupling remain unchanged.\",\n      \"method\": \"NGS diagnostics, RNA splicing analysis, in vitro GTP uptake and hydrolysis assays, protein-protein interaction assays, high-throughput drug screening\",\n      \"journal\": \"Med\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic characterization with structural interpretation and drug screening validation\",\n      \"pmids\": [\"37001522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The P170R Gαo mutant displays 100-fold accelerated GTP uptake without loss of GTP hydrolysis (biochemically distinct from all other encephalopathy mutants); Zn2+ uniquely forces the mutant to release bound GTP rather than restoring hydrolysis.\",\n      \"method\": \"In vitro GTP uptake and hydrolysis assays, Zn2+ treatment, protein interaction assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic characterization with mutagenesis; biochemically distinct mechanism demonstrated\",\n      \"pmids\": [\"37887313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Two Gαo subforms (Gαo-I and Gαo-II) were purified from bovine brain and shown to have distinct peptide maps and migration, with Gαo-II being the only form in NG 108-15 cell membranes; Gαo is highly enriched in nervous tissue and adrenal medulla.\",\n      \"method\": \"Protein purification, immunochemical characterization, in situ peptide mapping, tissue distribution by immunoblot\",\n      \"journal\": \"European Journal of Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical protein purification and characterization; foundational structural/distribution finding\",\n      \"pmids\": [\"2506013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GNAO1 G203R iPSC-derived cortical neurons show aberrant cell fate commitment, reduced early neural gene expression, increased astrocyte markers, premature and defective neuronal differentiation, lower basal intracellular Ca2+ concentration, reduced spontaneous activity frequency, and smaller responses to neurotransmitters.\",\n      \"method\": \"Patient-derived hiPSC differentiation, CRISPR-corrected isogenic controls, RNA-seq, Ca2+ imaging, electrophysiology\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isogenic CRISPR-corrected control with multiple orthogonal functional readouts; findings replicated in second unrelated patient with same variant\",\n      \"pmids\": [\"38434323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The C-terminal residue at position -3 (Gly) of Gαo is essential for productive interaction with the α2A-adrenoceptor; substitution with Glu (from Gαs) converts agonist clonidine from full agonist to antagonist for GTPγS binding, demonstrating that this single C-terminal residue constrains receptor-G protein coupling specificity.\",\n      \"method\": \"C-terminal mutagenesis of Gαo, [35S]GTPγS binding assay with co-expressed α2A-adrenoceptor in Sf9 cells\",\n      \"journal\": \"Molecular Pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — site-directed mutagenesis with functional binding assay; single study\",\n      \"pmids\": [\"11562427\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GNAO1 encodes Gαo, the most abundant G protein α-subunit in the mammalian brain, which couples GPCRs to multiple effectors: it inhibits N- and L-type voltage-gated Ca2+ channels (via direct N-terminus/α1A interaction and by Gβγ release), mediates mGluR6 signaling in retinal ON bipolar cells, drives pheromone transduction via V2R receptors in vomeronasal neurons, activates Rap1 (through Rap1GAPII proteasomal degradation) and sequential Ral→Src→Stat3 cascades for neurite outgrowth, mediates WNT-JNK planar cell polarity signaling through Dishevelled-1/3 and RhoA/Rac1/Cdc42, and is directly activated by reactive oxygen species; pathogenic GNAO1 mutations disrupt GTP cycling (accelerating uptake and/or blocking hydrolysis), impair Gβγ and RGS interactions, reduce plasma membrane localization, and gain neomorphic interactions with Ric8A/B chaperones, with loss-of-function alleles causing epileptic encephalopathy and gain-of-function alleles primarily causing hyperkinetic movement disorders.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GNAO1 encodes Gαo, the most abundant heterotrimeric G protein α-subunit in the mammalian nervous system, which couples diverse GPCRs to downstream effectors governing neuronal excitability, sensory transduction, neurite outgrowth, and myelination. Gαo inhibits N-type and L-type voltage-gated Ca²⁺ channels through both direct interaction with the α1A (Cav2.1) subunit and Gβγ release [PMID:7932231, PMID:11395521, PMID:9050846], is the obligate transducer of the mGluR6 cascade in retinal ON bipolar cells [PMID:11124982] and of V2R-mediated pheromone signaling in vomeronasal neurons [PMID:21768373], and drives neurite outgrowth via Rap1→Ral→Src→Stat3 and RhoA/Rac1/Cdc42 signaling downstream of cannabinoid and Wnt receptors [PMID:15657046, PMID:16046413, PMID:18187455]. De novo GNAO1 mutations cause childhood-onset neurological disease: loss-of-function alleles that impair GTP binding or plasma membrane localization produce epileptic encephalopathy, whereas gain-of-function alleles with accelerated GTP uptake or resistance to RGS-mediated GTPase acceleration primarily cause hyperkinetic movement disorders, and neomorphic interactions of mutant Gαo with Ric8A/B chaperones contribute to disease dominance [PMID:23993195, PMID:28747448, PMID:36206333, PMID:38874642].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of two biochemically distinct Gαo isoforms enriched in nervous tissue established Gαo as the predominant brain G protein α-subunit and raised the question of which signaling pathways it serves.\",\n      \"evidence\": \"Protein purification, peptide mapping, and immunoblot tissue survey from bovine brain\",\n      \"pmids\": [\"2506013\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional assay for either isoform\", \"No receptor coupling demonstrated\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Antibody microinjection demonstrated that Gαo (not Gαq/11) mediates α-adrenoceptor inhibition of N/L-type Ca²⁺ channels in sympathetic neurons, establishing the first direct effector link for Gαo.\",\n      \"evidence\": \"Intracellular anti-Gαo antibody injection with patch-clamp recording in rat SCG neurons\",\n      \"pmids\": [\"7932231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of channel inhibition (direct vs. Gβγ-mediated) not resolved\", \"Receptor-Gαo coupling specificity determinants unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Structural studies showed that the C-terminal region and N-terminal β-strands of Gαo determine its unique nucleotide-binding and conformational properties, distinguishing it from Gαi2.\",\n      \"evidence\": \"In vitro chimeric Gαo/Gαi2 analysis, native proteolysis, and nucleotide binding assays\",\n      \"pmids\": [\"7727415\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure available at this point\", \"Functional consequences of C-terminal truncation in vivo unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Gαo expression in a distinct subset of vomeronasal sensory neurons suggested a role in pheromone transduction via a dedicated GPCR cascade, though functional proof required later conditional knockout.\",\n      \"evidence\": \"In situ hybridization and immunohistochemistry in mouse VNO\",\n      \"pmids\": [\"8558259\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional ablation of Gαo in VNO neurons\", \"Specific pheromone ligands transduced by Gαo-expressing neurons not identified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Gαo knockout mice revealed that Gαo is required for muscarinic inhibition of L-type Ca²⁺ channels in ventricular myocytes, extending Gαo effector biology beyond neurons to the heart.\",\n      \"evidence\": \"Gαo−/− knockout mouse with whole-cell patch clamp in ventricular myocytes\",\n      \"pmids\": [\"9050846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of L-type channel regulation (direct vs. indirect) not established\", \"Cardiac phenotype at organ level not fully characterized\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Three contemporaneous studies resolved key coupling questions: Gαo is the essential G protein for the mGluR6 ON-bipolar cascade (ERG b-wave abolished in knockout), is directly activated by reactive oxygen species (H₂O₂ modifies Gαo causing subunit dissociation and Gβγ-dependent ERK activation), and couples to mu-opioid receptors in brain.\",\n      \"evidence\": \"Gαo−/− mouse ERG; in vitro GTPγS binding with purified Go plus H₂O₂; co-IP from solubilized rat brain\",\n      \"pmids\": [\"11124982\", \"11100733\", \"10693938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the ROS-modified residue(s) on Gαo unknown\", \"Downstream effectors of Gαo in ON bipolar cells not identified\", \"Mu-opioid receptor coupling shown only by co-IP, not by reconstitution\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The Gαo N-terminus was shown to directly bind the α1A (Cav2.1) Ca²⁺ channel subunit C-terminus, mediating voltage-resistant inhibition, while Gβγ mediates the voltage-dependent component — resolving a longstanding dual-mechanism question.\",\n      \"evidence\": \"In vitro peptide binding assay and intracellular peptide/antibody dialysis during patch-clamp recording\",\n      \"pmids\": [\"11395521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the Gαo–α1A interaction not resolved\", \"Relative contribution of each mechanism in intact synapses unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Two studies delineated a neurite outgrowth signaling cascade downstream of Gαo: Gαo promotes Rap1GAPII proteasomal degradation to activate Rap1, then Rap1→Ral→Src→Stat3 and Rac1→JNK→Stat3 drive neuritogenesis.\",\n      \"evidence\": \"Co-IP, proteasomal inhibitors, siRNA, dominant-negative/constitutively-active mutant epistasis in Neuro-2A cells\",\n      \"pmids\": [\"15657046\", \"16046413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this cascade operates in primary neurons in vivo not confirmed\", \"Direct Gαo–Rap1GAPII binding domain not mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Gαo was placed into the non-canonical Wnt-JNK/planar cell polarity pathway, coupling Wnt3a to RhoA/Rac1/Cdc42 through Dishevelled-1/3, independently of Gαq and canonical β-catenin signaling.\",\n      \"evidence\": \"Systematic epistasis with dominant-negatives, shRNA, and Rho GTPase activation assays in F9 teratocarcinoma cells\",\n      \"pmids\": [\"18187455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Frizzled receptor identity upstream of Gαo not defined\", \"In vivo PCP phenotype in Gnao1 mutants not demonstrated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Conditional Gαo deletion in vomeronasal neurons abolished electrophysiological responses to V2R ligands and eliminated territorial aggression, proving Gαo is the obligate transducer for this sensory modality; separately, the oncogenic R243H mutation was shown to constitutively activate Gαo by accelerating nucleotide exchange via disruption of a conserved R243-E43 salt bridge.\",\n      \"evidence\": \"Cre-loxP conditional KO with calcium imaging and behavioral assays; in vitro GTPase/exchange assays with mutagenesis and NIH-3T3 transformation\",\n      \"pmids\": [\"21768373\", \"21317923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether all V2R-class ligands require Gαo not tested\", \"R243H oncogenic pathway in human tumors not characterized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"De novo GNAO1 mutations were identified as a cause of epileptic encephalopathy; functional assays showed that destabilizing mutations impair plasma membrane localization while switch-II mutations impair GTP binding, both reducing Gαo-mediated Ca²⁺ channel inhibition.\",\n      \"evidence\": \"Whole-exome sequencing of affected children, transient expression with immunofluorescence and electrophysiology\",\n      \"pmids\": [\"23993195\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype correlation across full mutational spectrum not yet systematic\", \"Neuronal circuit-level mechanism of seizures not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"An RGS-insensitive Gαo knock-in (G184S) produced seizures and strain-dependent lethality, demonstrating that failure to terminate Gαo signaling suffices to cause epileptic encephalopathy.\",\n      \"evidence\": \"Genomic knock-in mouse with EEG recording and PTZ kindling\",\n      \"pmids\": [\"24700286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific RGS proteins responsible for Gαo turnoff in seizure-relevant circuits not identified\", \"Whether human RGS-resistance mutations exist not established at this time\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Systematic functional classification of 15 GNAO1 clinical variants established that loss-of-function mutations associate with epileptic encephalopathy and gain-of-function mutations with movement disorders, providing a molecular framework for genotype-phenotype correlation.\",\n      \"evidence\": \"cAMP inhibition assay with co-expressed α2A-adrenergic receptor in HEK-293T cells\",\n      \"pmids\": [\"28747448\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"cAMP is only one effector readout; other downstream pathways not tested\", \"Mixed phenotype patients not fully explained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Biochemical dissection of encephalopathy hotspot mutations (Gly203, Arg209, Glu246) revealed accelerated GTP uptake coupled with catalytic-residue (Gln205) displacement blocking hydrolysis, and Zn²⁺ was identified as a pharmacological corrector restoring GTPase activity; in parallel, C. elegans and mouse models confirmed dominant-negative activity of multiple pathological alleles.\",\n      \"evidence\": \"In vitro GTPase/exchange assays, Drosophila rescue, CRISPR knock-in in C. elegans and mouse with behavioral assays\",\n      \"pmids\": [\"36206333\", \"34508586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Zn²⁺ therapeutic window and CNS delivery not addressed\", \"Dominant-negative mechanism (e.g. Gβγ sequestration vs. effector titration) not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A comprehensive survey of >80 pathological Gαo variants uncovered neomorphic interactions with Ric8A and especially Ric8B chaperones (normally Gαs/olf-specific), which relocalize to the Golgi and correlate with disease severity — establishing chaperone sequestration as a disease-driving mechanism distinct from simple loss or gain of canonical function.\",\n      \"evidence\": \"Systematic co-IP and immunofluorescence across >80 variants\",\n      \"pmids\": [\"38874642\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Ric8B sequestration disrupts Gαs/olf signaling in patient neurons not directly tested\", \"Structural basis of neomorphic Ric8B binding not determined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Additional 2024 studies expanded the mechanistic spectrum: N-terminal Leu→Pro mutations uniquely block heterotrimer formation and GPCR coupling (associated with parkinsonism); Gαo regulates Rho GTPase-dependent cytoskeletal remodeling in developing neurons rescuable by ROCK inhibition; and Schwann cell-expressed Gαo negatively regulates myelination via cAMP/PI3K-AKT suppression.\",\n      \"evidence\": \"Biochemical heterotrimer assays; patient iPSC-derived neurons with ROCK inhibitor rescue; SC-specific conditional KO and overexpression mice with nerve injury remyelination\",\n      \"pmids\": [\"38358016\", \"39048611\", \"38331815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ROCK inhibitors have therapeutic potential for GNAO1 encephalopathy in vivo unknown\", \"Receptor(s) upstream of Gαo in Schwann cells not identified\", \"Parkinsonism phenotype documented in only two families\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of Gαo interactions with effectors and Ric8 chaperones, the identity of the specific neuronal circuits whose dysfunction produces seizures versus movement disorders, whether Zn²⁺ or ROCK inhibitors can be developed as therapeutics, and the in vivo relevance of the Rap1/Stat3 neurite outgrowth pathway.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of Gαo in complex with any effector or Ric8\", \"Circuit-level mechanisms linking Gαo dysfunction to seizures vs. dyskinesia unknown\", \"No clinical trial data for any GNAO1-targeted therapy\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [1, 9, 13, 20, 22, 33]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 3, 4, 8, 10]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 6, 11, 25, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 10, 22, 26]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [22, 23]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 3, 5, 6, 7, 8, 9, 18]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [3, 10, 11, 19, 27, 35]},\n      {\"term_id\": \"R-HSA-9709957\", \"supporting_discovery_ids\": [0, 2, 8, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 27, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 17, 18, 20, 21, 23]}\n    ],\n    \"complexes\": [\n      \"Heterotrimeric Go (Gαo/Gβγ)\"\n    ],\n    \"partners\": [\n      \"CACNA1A\",\n      \"GRM6\",\n      \"RAP1GAP2\",\n      \"DVL1\",\n      \"DVL3\",\n      \"RIC8A\",\n      \"RIC8B\",\n      \"SPTAN1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}